| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.9 | 0.2 |
| Net income | -28.8 | -26.8 |
| EPS (diluted, $ a share) | $-0.02 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +341.5% |
|---|
10-Q filed with the SEC, OTC: NWBO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Northwest Biotherapeutics Inc: key numbers
- Share price
- $0.1462Close, Nov 16
- Market cap
- $265M
- Shares outstanding
- 1.81BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Northwest Biotherapeutics Inc
All →Northwest Biotherapeutics $5.5M Debt Financing with Streeterville Capital, LLC
Northwest Biotherapeutics entered into a $5.505 million commercial loan agreement and note with Streeterville Capital, LLC. The loan carries an 8% annual interest rate, a 10% original issue discount, and a 22-month maturity with no repayments required for the first 8 months. Proceeds will be used to fund the company's ongoing business operations.
- Value
- $5.5M
- Counterparty
- Streeterville Capital, LLC
- Term
- 22 months